Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

BACKGROUND: Cabazitaxel significantly improves overall survival (OS) versus mitoxantrone in patients with metastatic castration-resistant prostate cancer after docetaxel failure. We examined patient survival at 2 years and tumour-related pain with cabazitaxel versus mitoxantrone. METHODS: Updated TR...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahl, A., Oudard, S., Tombal, B., Özgüroĝlu, M., Hansen, S., Kocak, I., Gravis, G., Devin, J., Shen, L., de Bono, J. S., Sartor, A. O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755329/
https://www.ncbi.nlm.nih.gov/pubmed/23723295
http://dx.doi.org/10.1093/annonc/mdt194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755329/
https://www.ncbi.nlm.nih.gov/pubmed/23723295
http://dx.doi.org/10.1093/annonc/mdt194

Ejemplares similares